EZH2 PROTAC Compound for Selective Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological approaches to inhibit EZH2, a key protein implicated in various cancers, face challenges in overcoming drug resistance and effectively degrading the protein, necessitating new therapeutic strategies that can selectively target and remove EZH2.
Innovation Solution
Development of a pharmaceutical composition comprising an EZH2 inhibitor and an E3 ligase binder, utilizing PROTAC technology to induce selective proteolysis of EZH2 through the ubiquitin-proteasome pathway, leveraging a compound represented by specific molecular structures to connect the EZH2 inhibitor with an E3 ligase binder.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EZH2 inhibitors are used to treat cancers, then antiproliferative activity is improved, but drug resistance develops
Solution Approach 1:
Instead of inhibiting EZH2 function, the patent inverts the approach by targeting EZH2 for complete degradation through the ubiquitin-proteasome pathway. The compound recruits E3 ligase to ubiquitinate EZH2, leading to its proteasomal degradation rather than simple functional inhibition, thereby overcoming resistance mechanisms that develop against traditional inhibitors.
Solution Approach 2:
The patent introduces an E3 ligase as an intermediary component in the therapeutic mechanism. The compound acts as a molecular bridge that recruits E3 ligase to the EZH2 target, enabling selective ubiquitination and degradation. This intermediary approach allows for more specific and controllable protein removal compared to direct inhibition.
2Reliability
If traditional inhibition methods are used, then EZH2 function is blocked, but protein degradation is not achieved
Solution Approach 1:
The patent replaces the mechanical inhibition approach (blocking EZH2 activity) with a biochemical degradation system. Instead of physically blocking the enzyme's active site, the compound utilizes the cell's natural ubiquitin-proteasome degradation machinery to eliminate EZH2 protein entirely, achieving both functional inhibition and protein removal.
Solution Approach 2:
The patent leverages the cell's own protein degradation system (ubiquitin-proteasome pathway) to eliminate EZH2. Rather than introducing an external degradation mechanism, the compound recruits endogenous E3 ligase and utilizes the cell's existing proteasomal machinery to carry out the degradation, making the process self-service and biologically integrated.
3Reliability
If EZH2 is degraded selectively, then therapeutic efficacy is enhanced, but mechanism complexity increases
Solution Approach 1:
The patent utilizes the universal ubiquitin-proteasome pathway, which is a common protein degradation mechanism used by cells for numerous different proteins. By hijacking this pre-existing, multi-functional degradation system, the compound achieves selective EZH2 degradation without needing to create a new, complex degradation machinery from scratch.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively degrades EZH2, offering a potential treatment for EZH2-related diseases and cancers by selectively targeting and removing the protein, thereby overcoming drug resistance and enhancing therapeutic efficacy.
Implementation Method 1
utilizing PROTAC technology to induce selective proteolysis of EZH2 through the ubiquitin-proteasome pathway
Data Source
AI summary
The present invention relates to a compound comprising an EZH2 inhibitor and an E3 ligase binder, and a pharmaceutical composition for preventing or treating EZH2-associated disease and a pharmaceutical composition for selective protein degradation containing the same as an active ingredient. Since the compound of the present invention can selectively degrade EZH2, it can be effectively used for the treatment of EZH2-related diseases and cancers, particularly, cancers in which EZH2 is overexpressed, and can be usefully used for the selective degradation of EZH2.